DTIL stock forecast, quote, news & analysis
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies... Show more
Why Precision BioSciences (DTIL) Is Up +24% in the Last 30 Days
Key Takeaways
- DTIL stock surged +24% over the past 30 days, driven by positive clinical updates and FDA Fast Track designation for PBGENE-DMD.
- Over the past quarter, shares rose +49%, reflecting strong momentum from earnings beats and pipeline advancements in gene editing therapies.
- Key catalysts include Q4 2025 earnings surpassing estimates, preclinical data presentations, and patent allowances for PBGENE-HBV.
- Biotech sector sentiment and investor focus on ARCUS platform fueled the upward price movement.
- Cash position of $137 million supports runway through 2028, bolstering confidence amid volatile market trends.
Precision BioSciences (DTIL) Company Overview and Market Position
Precision BioSciences, Inc. (DTIL) is a clinical-stage biotechnology company developing in vivo gene editing therapies using its proprietary ARCUS genome editing platform. ARCUS enables precise DNA insertion, correction, and deletion for treating diseases like chronic hepatitis B (HBV) and Duchenne muscular dystrophy (DMD). The company's pipeline features lead candidates PBGENE-HBV and PBGENE-DMD, targeting high-unmet-need areas in infectious diseases and rare genetic disorders. In the competitive gene editing landscape, Precision differentiates through ARCUS's smaller size for better delivery and higher specificity, reducing off-target risks compared to rivals like CRISPR-based therapies. These fundamentals, including recent clinical progress, underpin the stock's recent strength amid broader biotech market trends.
Precision BioSciences (DTIL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, DTIL stock climbed +24%, from approximately $5.35 to $6.61, exhibiting volatile but trend-driven gains with multiple multi-day surges. The movement was punctuated by sharp increases tied to news events, amid elevated trading volume averaging over 250,000 shares daily.
For the past quarter, shares advanced +49%, recovering from early-year lows around $3.92 to the current $6.61 level. The uptrend was steady post-February lows, with reduced volatility and consistent higher highs, outperforming the broader biotech sector.
What Drove DTIL Stock Price in the Last 30 Days
The 30-day rally was propelled by a series of pipeline milestones. On March 9, the FDA granted Fast Track designation to PBGENE-DMD for DMD, accelerating development and sparking a sharp uptick. This was followed by preclinical data presented on March 10 at the Muscular Dystrophy Association conference, demonstrating durable dystrophin expression and functional benefits, enhancing investor optimism. Patent allowances for PBGENE-HBV on March 11 extended IP protection to 2044, reducing competitive risks. Q4 and full-year 2025 earnings on March 12 beat expectations with $0.36 EPS versus a forecasted loss and $34.2 million revenue, alongside a $137 million cash runway through 2028. These events shifted market sentiment positively, driving volume spikes and the +24% gain in a biotech-favorable environment.
What Drove DTIL Stock Performance Over the Last Quarter
The quarterly +49% rise built on broader narratives, starting from January lows near $3.92 amid market lows. Key sustained drivers included IND clearance for PBGENE-DMD in February, enabling Phase 1/2 trial initiation, and ongoing PBGENE-HBV Phase 1 data from the ELIMINATE-B trial showing safety and antiviral activity. A $7.5 million milestone from TG Therapeutics for azer-cel in March added non-dilutive funding. Macro factors like biotech sector recovery and interest rate stability supported risk-on sentiment. Institutional interest grew, with analyst targets averaging $32, reflecting confidence in ARCUS's competitive edge. Cumulative clinical and financial positives outweighed earlier Q3 losses, propelling the steady uptrend.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, each analyzing thousands of tickers across diverse strategies like trend-following, mean reversion, and momentum plays. These bots vary by timeframe—from intraday scalps to long-term swings—and key metrics such as win rate, Sharpe ratio, and max drawdown. Curated for relevance and recent outperformance, the section highlights bots excelling in current market conditions, aiding traders in selecting tools aligned with their risk profiles and goals. Explore the page to discover bots potentially suited for biotech volatility like DTIL and enhance your trading edge today.
DTIL Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming Phase 1 data readouts for PBGENE-HBV from additional ELIMINATE-B cohorts, expected in 2026, alongside PBGENE-DMD trial initiation progress. Earnings releases will detail cash burn and milestone inflows, such as potential azer-cel payments. Industry trends in gene editing, including competitor data and regulatory shifts, could sway sentiment. Macro factors like interest rates and biotech funding environments remain key. Strategic developments, including partnerships or IND updates, alongside risks from clinical setbacks or dilution, warrant close attention for shifts in stock analysis and price movement.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Aroon Indicator for DTIL shows an upward move is likely
DTIL's Aroon Indicator triggered a bullish signal on May 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 80 similar instances where the Aroon Indicator showed a similar pattern. In of the 80 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DTIL's RSI Indicator exited the oversold zone, of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 66 cases where DTIL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DTIL advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .
DTIL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DTIL as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for DTIL turned negative on May 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
DTIL moved below its 50-day moving average on May 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DTIL crossed bearishly below the 50-day moving average on June 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DTIL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DTIL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.269) is normal, around the industry mean (19.567). P/E Ratio (4.529) is within average values for comparable stocks, (35.932). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.687). DTIL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (2.536) is also within normal values, averaging (355.865).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DTIL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technology to produce custom, genome-editing enzymes for human health and biological research
Industry Biotechnology